90 Second Review: 2015 Outlook for Biotech

Foreseeable Boost for Biotechnology

This week's Nasdaq Corporate Solutions Advisory Services commentary features Joe Rosenberg, healthcare and biotechnology specialist, delivering his outlook for the biotechnology sector in 2015:

  • Accommodating regulatory environment - the FDA approved 41 new drugs during 2014, the largest number of yearly approvals in at least a decade.
  • 2015 promises to be a big year for M&A - companies will seek to expand their portfolios of marketed drugs, grow their R&D pipelines, and complement existing businesses.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.